

RESEARCH ARTICLE

Prediction of functional phosphorylation sites by incorporating evolutionary information

Shen Niu^{1*}, Zhen Wang^{1*}, Dongya Ge^{1*}, Guoqing Zhang^{1,2}✉, Yixue Li^{1,2}✉

¹ Key Laboratory of Systems Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China

² Shanghai Center for Bioinformation Technology, Shanghai 200235, China

✉ Correspondence: gqzhang@sibit.org (G. Zhang), yxli@sibs.ac.cn (Y. Li)

Received May 21, 2012 Accepted June 27, 2012

ABSTRACT

Protein phosphorylation is a ubiquitous protein post-translational modification, which plays an important role in cellular signaling systems underlying various physiological and pathological processes. Current *in silico* methods mainly focused on the prediction of phosphorylation sites, but rare methods considered whether a phosphorylation site is functional or not. Since functional phosphorylation sites are more valuable for further experimental research and a proportion of phosphorylation sites have no direct functional effects, the prediction of functional phosphorylation sites is quite necessary for this research area. Previous studies have shown that functional phosphorylation sites are more conserved than non-functional phosphorylation sites in evolution. Thus, in our method, we developed a web server by integrating existing phosphorylation site prediction methods, as well as both absolute and relative evolutionary conservation scores to predict the most likely functional phosphorylation sites. Using our method, we predicted the most likely functional sites of the human, rat and mouse proteomes and built a database for the predicted sites. By the analysis of overall prediction results, we demonstrated that protein phosphorylation plays an important role in all the enriched KEGG pathways. By the analysis of protein-specific prediction results, we demonstrated the usefulness of our method for individual protein studies. Our method would help to characterize the most likely functional phosphorylation sites for further studies in this research area.

KEYWORDS protein, phosphorylation, function, conser-

vation, evolution

INTRODUCTION

Protein phosphorylation is a kind of post-translational modification and has been shown to be one of the most essential regulatory and signaling mechanisms in the cell (Zolnierowicz and Bollen, 2000). The process is catalyzed by protein kinases, in which the γ phosphate on ATP or GTP is transferred to the substrates. In eukaryotic cells, phosphorylation usually takes place on Serine (S), Threonine (T) or Tyrosine (Y) of the substrate protein. The phosphate on substrates can be removed by phosphatases, so the phosphorylation process is reversible: it is determined by the balance between the protein kinases and phosphatases. This reversible character allows the phosphorylation process to work like a switch in a living cell. Specific substrates could be activated by protein kinases under the simulation of an external signal. After the signal wanes, the activated substrates could be inactivated by phosphatases and wait for the next signal. Phosphorylation can regulate a variety of important protein functions, including subcellular localization, protein degradation and stabilization, as well as biochemical activities (Cohen, 2000; Ficarro et al., 2002; Manning et al., 2002a; Zannini et al., 2012). There are usually a series of phosphorylation processes involved in a normal biological function *in vivo* (Ubersax and Ferrell, 2007; Cai et al., 2012). It was also implicated in various pathological processes, such as cancer (Finn and Lu, 2008; Ollila and Makela, 2011, insulin resistance (Tanti and Jager, 2009), polyglutamine disease (Zhou et al., 2008) and Alzheimer's disease (Chung, 2009).

In an eukaryotic cell, about 30%–50% of the proteins can be phosphorylated (Pinna and Ruzzene, 1996). There are

*These authors contributed equally to the work.

also hundreds of kinases within an eukaryotic genome, for instances: 518 protein kinases in humans (Manning et al., 2002b), 540 kinases in mice (Caenepeel et al., 2004) and 251 kinases in *Drosophila* (Morrison et al., 2000). The enzymes must be specific and act only on a defined subset of cellular targets to ensure signal fidelity. Cells must have a mechanism to control the phosphorylation process involving so many kinases and protein substrates simultaneously and precisely. This mechanism is mainly realized by the specific recognition of protein kinases to substrates, which determines the exact time and place for phosphorylation to occur. Thus, the identification of the involved kinases and their phosphorylation sites is the first step to understand the mechanism.

Currently there are a number of computational methods for phosphorylation site prediction. Generally, these methods can be divided into two categories: non-kinase-specific and kinase-specific phosphorylation site prediction. For non-kinase-specific phosphorylation site prediction, there exist NetPhos (Blom et al., 1999), DISPHOS (Iakoucheva et al., 2004), PHOSIDA (Gnad et al., 2007), etc.. For kinase-specific phosphorylation site prediction, there exist GPS (Xue et al., 2010), NetPhosK (Blom et al., 2004), KinasePhos (Wong et al., 2007), PPSP (Xue et al., 2006), etc.. Although these methods could predict whether S/Y/T sites could be phosphorylated or not, they cannot predict whether a phosphorylation site is functional or not, which is a major issue for further experimental researches.

For the phosphorylation sites with known functions, it had been demonstrated that they are under strong functional constraints and are evolutionarily more conserved than those with no characterized functions (Landry et al., 2009; Ba and Moses, 2010). So the evolutionary information of S/Y/T sites can be incorporated to identify the most likely functional phosphorylation sites. Since most phosphosites occur in

disordered regions and the conservation of phosphorylation sites is also influenced by the region in which the residue is located (Landry et al., 2009), it is necessary to consider the relative conservation of an S/Y/T site against its flanking region. Based on these considerations, we developed a prediction method that incorporated both absolute and relative conservation information of S/Y/T sites to facilitate the identification of the most likely functional phosphorylation sites.

RESULTS

Web server development

We developed a web server, which incorporated NetPhos (Blom et al., 1999) and NetPhosK (Blom et al., 2004) to predict general and kinase-specific phosphorylation sites. Users can also upload prediction results from other phosphorylation site prediction tools as a formatted table (the table template can be downloaded from the web server). PhosphoSitePlus (Hornbeck et al., 2012) was incorporated to mark whether a predicted phosphorylation site is experimentally validated or not. Then, the server calculated the absolute and relative conservation score for each possible phosphorylation site with Rate4site. Both scores were normalized to the range of 0-1, and the larger the relative and absolute conservation score is, the more likely the phosphorylation site is functional. The access of the web server is "http://lifecenter.sgst.cn/ppps/en/home.do". Using the web server, users could predict most likely functional phosphorylation sites using UniProt ID, the query box is shown as Fig. 1, and the query result is shown as Fig. 2. The web server could also search the predicted results in the constructed human, rat and mouse database and the query box is shown as Fig. 3. Users could also search the database by a specific kinase and the query box is shown as Fig. 4.

→ Online Analysis

Analysis based on exist prediction results.
Please upload the protein name or accession of human, mouse and rat.
 Example

Note: protein name or accession includes:
please separate accessions by comma(,), semicolon(;) or space().

Only process kinase specificity phosphorylation prediction:

Analysis based on prediction results from other software:
Please upload the prediction results. Browse... Template Example

Note: Please ensure the format of uploaded file is identical to the template.

Online Analysis Reset

Figure 1. The search box for prediction of more likely functional phosphorylation sites by UniProt IDs




Figure 2. The prediction results of the web server.




Figure 3. Search in the constructed human, rat and mouse database.




Figure 4. Kinase-specific search in the constructed human, rat and mouse database.

Human, rat and mouse database construction

We selected the phosphorylation sites predicted by both NetPhos and GPS (Xue et al., 2010), and the conservation scores could be calculated to construct the human, rat and mouse database. For human, rat and mouse proteome, the number of the phosphorylation sites predicted by NetPhos, GPS or both, and the statistics of the final database are shown in Table 1. The “Database sites” column indicates the selected predicted phosphorylation sites in the database. The “Protein sequences” column indicates the number of protein sequences containing the selected predicted phosphorylation sites in the database. The “Experimentally validated sites” column indicates the number of experimentally validated phosphorylation sites in the database.

Analysis of relative and absolute conservation scores of human, rat and mouse database

We compared the density distribution of the relative and absolute conservation score of human, rat and mouse database

using R stats package (Fig. 5). The density distribution of the relative conservation score of human, rat and mouse are consistent, the density distribution of the absolute conservation score are also consistent. For both relative and absolute conservation score density distribution, there are two peaks: one at about 0.025 and one at about 0.80. So our method not only can predict which phosphorylation sites are most likely to be functional, but also can give clues to which phosphorylation sites are least likely to be functional, thus can help relevant researchers to select more conserved and important phosphorylation sites to perform further studies. The density distribution of the relative and absolute conservation score intersect at about 0.85. For conservation score larger than 0.85, the distribution density of the relative conservation score is larger than the absolute conservation score. It may be explained that some phosphorylation sites are more conserved against its flanking region than against the overall protein sequence. For the majority of conservation score less than 0.85, the distribution density of the absolute conservation score is larger than the relative conservation score, indicating that some phosphorylation sites are less conserved

Table 1 Statistics of the constructed human, rat and mouse database

	NetPhos predicted sites	GPS predicted sites	Both predicted sites	Database sites	Protein sequences	Experimentally validated sites
Human	657160	1774630	650289	551104	17771	28339
Rat	826362	2227169	816504	282438	12726	1064
Mouse	1064226	2885697	1053162	355280	14715	7938




Figure 5. The density distribution of the relative and absolute conservation score of human, rat and mouse database.

against their flanking region than against the overall protein sequence. Previous studies showed that the conservation of phosphorylation sites is also influenced by the region in which the residue is located (Landry et al., 2009), the density distribution of the absolute and relative conservation score also demonstrated that it is necessary to consider both the relative and absolute conservation of an S/Y/T site against its flanking region and the overall protein sequence, respectively.

General prediction results

We used the selected proteins as mentioned in the Materials and methods section to do the KEGG pathway enrichment analysis. The results for human, rat and mouse are shown in Table 2, Table 3 and Table 4, respectively. We found that the functions of protein phosphorylation in all the enriched KEGG pathways are supported by previous studies.

Table 2 Enriched KEGG pathways for selected human proteins

KEGG ID	P value	KEGG Term	References
04110	0.000	Cell cycle	Bradbury et al., 1974; Lee et al., 1988; Atherton-Fessler et al., 1993; Lew and Kornbluth, 1996; Matsuo et al., 1998; Konishi et al., 2002; Yu and Chen, 2004
05215	0.000	Prostate cancer	Haldar et al., 1996; Lin et al., 2002; El Sheikh et al., 2004; Jiang et al., 2004; Kreisberg et al., 2004; Jaggi et al., 2005; Chen et al., 2006; Shimada et al., 2006; Mahajan et al., 2007; Bianchini et al., 2008
04520	0.000	Adherens junction	Volberg et al., 1992; Collares-Buzato et al., 1998; Andriopoulou et al., 1999; Gomez et al., 1999; Tinsley et al., 1999; Serres et al., 2000; Shasby et al., 2002
04910	0.000	Insulin signaling pathway	Myers et al., 1998; Zick, 2001; Aguirre et al., 2002; Andrezzi et al., 2004; Ueki et al., 2004; Gual et al., 2005; McManus et al., 2005; Ueno et al., 2005; D'Alessandris et al., 2007; Wang et al., 2007
03013	0.000	RNA transport	Aubol et al., 2004; Topisirovic et al., 2004
03040	0.000	Spliceosome	Mermoud et al., 1994; Wang et al., 1999; Mathew et al., 2008
05200	0.000	Pathways in cancer	Foster and Wimalasena, 1996; Itoh et al., 2002; Viglietto et al., 2002; Vivanco and Sawyers, 2002; Altomare et al., 2004; Viatour et al., 2005; Cicens, 2008
05213	0.000	Endometrial cancer	Kleinman et al., 1996; Kanamori et al., 2001; Terakawa et al., 2003
05220	0.000	Chronic myeloid leukemia	Oda et al., 1996; Coluccia et al., 2007; Jilani et al., 2008; Jalkanen et al., 2011; Zhang et al., 2012
04810	0.000	Regulation of actin cytoskeleton	Arber et al., 1998; Sumi et al., 1999; Head et al., 2003; Vardouli et al., 2005; Park et al., 2012
04114	0.000	Oocyte meiosis	Dekel, 1996; Fan et al., 2002; Wang et al., 2006a; Liang et al., 2007; Swain and Smith, 2007
05223	0.000	Non-small cell lung cancer	Lee et al., 2002; Cappuzzo et al., 2004; Kim et al., 2005; Tang et al., 2006; Tsurutani et al., 2006
04012	0.000	ErbB signaling pathway	Sweeney and Carraway, 2000; El Sheikh et al., 2004; Fan et al., 2005; Schmidt et al., 2011
04530	0.000	Tight junction	Nigam et al., 1991; Collares-Buzato et al., 1998; Shen et al., 2006; Wang et al., 2006b; Aono and Hirai, 2008; Rao, 2009; Sallee and Burridge, 2009
04144	0.000	Endocytosis	Slepnev et al., 1998; Nucifora and Fox, 1999; Cousin et al., 2001; Whistler et al., 2001; Schaefer et al., 2002; Collawn, 2006; Zhu et al., 2007; Clayton et al., 2010
05214	0.000	Glioma	Oude Weernink et al., 1996; Nakada et al., 2004; Bornhauser and Lindholm, 2005; McDonough et al., 2005; van der Horst et al., 2005; Nakada et al., 2010; Feng et al., 2011
04120	0.000	Ubiquitin mediated proteolysis	Willems et al., 1996; Skowyra et al., 1997; Willems et al., 1999; Karin and Ben-Neriah, 2000; Koepp et al., 2001; Busino et al., 2004
04914	0.000	Progesterone-mediated oocyte maturation	Mulner et al., 1985; Muslin et al., 1993; Nebreda et al., 1995; Ju et al., 2002
05212	0.000	Pancreatic cancer	Ng et al., 2001; Adachi et al., 2010; Deming et al., 2010; Nakashima et al., 2011; Vo et al., 2011; Zheng et al., 2011; Ma et al., 2012
04270	0.000	Vascular smooth muscle contraction	Walker et al., 1994; Zhang et al., 1994; Hirano et al., 2004; Kordowska et al., 2006; Anfinogenova et al., 2007
05219	0.000	Bladder cancer	Yamamoto et al., 2006; Miyata et al., 2009; Szanto et al., 2009; Wang et al., 2010; Khadjavi et al., 2011; Ou et al., 2011
04010	0.000	MAPK signaling pathway	Aubin et al., 2004; Mylonis et al., 2006; Carriere et al., 2008; Junttila et al., 2008; Matsumoto et al., 2008; Kim et al., 2011; Li et al., 2011
04510	0.000	Focal adhesion	Kornberg et al., 1992; Calalb et al., 1995; Chen et al., 1996; Slack, 1998; Tang et al., 1999; Brunton et al., 2005; Mimura et al., 2005
04720	0.000	Long-term potentiation	Atkins et al., 1997; Barria et al., 1997; Fujii et al., 2000; Manabe et al., 2000; Lonart et al., 2003; Serrano et al., 2005; Bouzioukh et al., 2007; Capron et al., 2007; Schafe et al., 2008
04150	0.000	mTOR signaling pathway	Altomare et al., 2004; Acosta-Jaquez et al., 2009; Copp et al., 2009; Kruck et al., 2010; Rosner et al., 2010; Dai et al., 2011

Table 3 Enriched KEGG pathways for selected rat proteins

KEGG ID	P value	Term	References
04722	0.000	Neurotrophin signaling pathway	Mutoh et al., 2000; Wang et al., 2000; Viegi et al., 2002; Arevolo et al., 2006; Butowt and von Bartheld, 2009; Zhang et al., 2009
04910	0.000	Insulin signaling pathway	Myers et al., 1998; Zick, 2001; Aguirre et al., 2002; Andreozzi et al., 2004; Ueki et al., 2004; Gual et al., 2005; McManus et al., 2005; Ueno et al., 2005; D'Alessandris et al., 2007; Wang et al., 2007
04720	0.000	Long-term potentiation	Atkins et al., 1997; Barria et al., 1997; Fujii et al., 2000; Manabe et al., 2000; Lonart et al., 2003; Serrano et al., 2005; Bouzioukh et al., 2007; Capron et al., 2007; Schafe et al., 2008
04012	0.000	ErbB signaling pathway	Sweeney and Carraway, 2000; El Sheikh et al., 2004; Fan et al., 2005; Schmidt et al., 2011
05214	0.000	Glioma	Oude Weernink et al., 1996; Nakada et al., 2004; Bornhauser and Lindholm, 2005; McDonough et al., 2005; van der Horst et al., 2005; Nakada et al., 2010; Feng et al., 2011
04810	0.000	Regulation of actin cytoskeleton	Arber et al., 1998; Sumi et al., 1999; Head et al., 2003; Vardouli et al., 2005; Park et al., 2012
04270	0.001	Vascular smooth muscle contraction	Walker et al., 1994; Zhang et al., 1994; Hirano et al., 2004; Kordowska et al., 2006; Anfinogenova et al., 2007
05223	0.001	Non-small cell lung cancer	Lee et al., 2002; Cappuzzo et al., 2004; Kim et al., 2005; Tang et al., 2006; Tsurutani et al., 2006

Table 4 Enriched KEGG pathways for selected mouse proteins

KEGG ID	P value	Term	References
04530	0.000	Tight junction	Nigam et al., 1991; Collares-Buzato et al., 1998; Shen et al., 2006; Wang et al., 2006b; Aono and Hirai, 2008; Rao, 2009; Sallee and Burridge, 2009
04510	0.000	Focal adhesion	Kornberg et al., 1992; Calalb et al., 1995; Chen et al., 1996; Slack, 1998; Tang et al., 1999; Brunton et al., 2005; Mimura et al., 2005
04012	0.000	ErbB signaling pathway	Sweeney and Carraway, 2000; El Sheikh et al., 2004; Fan et al., 2005; Schmidt et al., 2011
04670	0.000	Leukocyte transendothelial migration	Alevriadou, 2003; Allingham et al., 2007; Barberis et al., 2009; Muller, 2009; Fernandez-Borja et al., 2010
04520	0.000	Adherens junction	Volberg et al., 1992; Collares-Buzato et al., 1998; Andriopoulou et al., 1999; Gomez et al., 1999; Tinsley et al., 1999; Serres et al., 2000; Shasby et al., 2002
04910	0.000	Insulin signaling pathway	Myers et al., 1998; Zick, 2001; Aguirre et al., 2002; Andreozzi et al., 2004; Ueki et al., 2004; Gual et al., 2005; McManus et al., 2005; Ueno et al., 2005; D'Alessandris et al., 2007; Wang et al., 2007
04810	0.000	Regulation of actin cytoskeleton	Arber et al., 1998; Sumi et al., 1999; Head et al., 2003; Vardouli et al., 2005; Park et al., 2012
05213	0.001	Endometrial cancer	Kleinman et al., 1996; Kanamori et al., 2001; Terakawa et al., 2003

Enrichment analysis for human

For the human proteome, we selected a total of 1755 proteins containing 2834 predicted phosphorylation sites (the selection criteria of top 10% is 0.918232). We matched the 1755 selected UniProt protein IDs to their gene ids using the R package *org.Hs.eg.db* and used all the gene ids in the *org.Hs.egUNIPROT* table within this R package as the background. The cutoff of the *P* value in the enrichment analysis was set to 0.001. There are 25 enriched KEGG pathways (Table 2), in all of which protein phosphorylation has been demonstrated to play important roles, as shown in the References column of Table 2.

Enrichment analysis for rat

For the rat proteome, we selected a total of 85 protein sequences containing 107 predicted phosphorylation sites (the selection criteria of top 10% is 0.923121). We matched the 85 selected UniProt protein IDs to their gene ids using the R

package *org.Rn.eg.db* and used all the gene ids in the *org.Rn.egUNIPROT* table within this R package as the background. The cutoff of the *P* value in the analysis was set to 0.001. There are 8 enriched KEGG pathways (listed in Table 3) for the selected rat proteins. The important roles of protein phosphorylation in all of these KEGG pathways had been supported by previous studies.

Enrichment analysis for mouse

For the mouse proteome, we selected a total of 555 protein sequences containing 794 predicted phosphorylation sites (the selection criteria of top 10% is 0.917137). We matched the 555 selected UniProt protein IDs to their gene ids using the R package *org.Mm.eg.db* and used all the gene ids in the *org.Mm.egUNIPROT* table within this R package as the background. The cutoff of the *P* value in the analysis was set to 0.001. There are 8 enriched KEGG pathways (Table 4) for the selected mouse proteins. The important roles of protein phosphorylation in all of these enriched KEGG pathways

have been supported by previous studies.

Protein specific prediction results

We used two well-studied proteins, p53 and Cyclin-dependent kinase inhibitor 1B, in which phosphorylation plays an important role, to demonstrate the usefulness of our method for individual protein phosphorylation studies.

p53

Our method totally predicted 23 phosphorylation sites in p53 (Table 5). We ranked the predicted phosphorylation sites by their relative conservation scores. Within these 23 sites, 14 sites have been experimentally validated to be phosphorylated. And according to the annotation of UniProt (Version 196), 9 phosphorylation sites have been supported to be functional. Our method predicted 5 of these 9 functional phosphorylation sites (site 15, 46, 392, 315 and 9). The ranks of the relative conservation score of these 5 sites were 2, 3, 5, 6 and 19, respectively. p53 serine 15 phosphorylation could direct its interaction with B56 γ and the tumor suppressor activity of B56 γ -specific protein phosphatase 2A (Shouse et al., 2008). p53 serine 46 could be

phosphorylated by HIPK2 upon UV irradiation, which could regulate p53 apoptotic activity and is required for acetylation by CREBBP (D'Orazi et al., 2002; Hofmann et al., 2002; Chang et al., 2005; Lee et al., 2009). Phosphorylation at serine 9 by HIPK4 could increase the repression activity of p53 at p53 repressive promoters (Arai et al., 2007). Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53 and could stimulate the DNA-binding ability of p53 (Sakaguchi et al., 1997; Kapoor et al., 2000). Phosphorylation of p53 at serine 315 after irradiation damage could stimulate p53-dependent transcription (Blaydes et al., 2001).

We can see that 4 of these 5 sites were within the top 6 sites ranked by the relative conservation score. For site 9, it may be explained that the function of site 9 phosphorylation is relatively less important for biological activities and a previous study has demonstrated that the specific recognition of Ser9 appears to be dependent upon additional determinants of p53 beyond the N-terminal 65 amino acids (Soubeyrand et al., 2004). But for site 9, we can also find that the relative conservation score (0.3185200) is much larger than the absolute conservation score (0.1658500), indicating it is more conserved against its flanking region than against the overall protein sequence.

Table 5 Predicted p53 phosphorylation sites

Rank	Sequence	Site	Residue	Validated	Absolute conservation score	Relative conservation score
1	P04637	303	S	no	0.6791800	0.8640700
2	P04637	15	S	yes	0.7778000	0.8542900
3	P04637	46	S	yes	0.5023500	0.8389500
4	P04637	211	T	no	0.8468500	0.8309000
5	P04637	392	S	yes	0.8517600	0.8048300
6	P04637	315	S	yes	0.6791800	0.7976600
7	P04637	284	T	no	0.8468500	0.7892800
8	P04637	215	S	yes	0.8517600	0.7698900
9	P04637	121	S	no	0.8517600	0.7693900
10	P04637	269	S	no	0.8517600	0.7678400
11	P04637	366	S	yes	0.5387800	0.6999100
12	P04637	376	S	yes	0.4991900	0.6883600
13	P04637	163	Y	no	0.7719500	0.6545700
14	P04637	183	S	no	0.6474700	0.4546000
15	P04637	99	S	yes	0.4991900	0.4506600
16	P04637	155	T	yes	0.4119200	0.3710500
17	P04637	9	S	yes	0.1658500	0.3185200
18	P04637	260	S	no	0.5472000	0.3151700
19	P04637	304	T	no	0.2678600	0.2932800
20	P04637	371	S	yes	0.1512700	0.1801200
21	P04637	377	T	yes	0.2521900	0.1721600
22	P04637	150	T	yes	0.0648860	0.0831870
23	P04637	81	T	yes	0.0071032	0.0081448

Cyclin-dependent kinase inhibitor 1B

For cyclin-dependent kinase inhibitor 1B, our method predicted totally 19 phosphorylation sites (Table 6), within which 10 sites have been experimentally validated. According to the annotation of UniProt (Version 138), a total of 5 phosphorylation sites have been supported to be functional. Our method predicted 3 of these 5 functional phosphorylation sites, i.e. site 187, 10 and 198. The rank of the relative conservation score of these 3 sites were 2, 6 and 12, respectively. Phosphorylation of threonine 187 leads to protein ubiquitination and proteasomal degradation (Boehm et al., 2002; Fujita et al., 2002; Motti et al., 2004; Hao et al., 2005; Sabile et al., 2006). Phosphorylation of serine 10 is the major site of phosphorylation in resting cells, which takes place at the G(0)-G1 phase and leads to protein stability (Boehm et al., 2002; Fujita et al., 2002; Motti et al., 2004). Phosphorylation of threonine 198 is required for interaction with 14-3-3 proteins (Fujita et al., 2002, 2003; Motti et al., 2004). The relative conservation scores of all these three sites were larger than 0.7. The high relative conservation score of other sites may be explained by the possibility that the function of these sites may not have been studied or these sites may not work by phosphorylation directly. However there were also 6 predicted phosphorylation sites with relative conservation scores less than 0.2. It may give further studies a clue that researchers could pay less attention to these sites than those having higher conservation scores.

DISCUSSION

In this work, a prediction web server was developed to facilitate the identification of the most likely functional protein phosphorylation sites by incorporating both the absolute and relative evolutionary conservation scores. The larger the relative and absolute conservation score is, the more likely the phosphorylation sites is functional. To facilitate the usage of our method, we also selected and integrated two existing computational methods: NetPhos and NetPhosK for general and kinase-specific phosphorylation site prediction, respectively. Using our method, we predicted the most likely functional sites of the human, rat and mouse proteomes and built a database for the predicted phosphorylation sites. By the analysis of overall prediction results, we demonstrated that protein phosphorylation plays an important role in all the enriched KEGG pathways. By the analysis of protein-specific prediction results, we also demonstrated the usefulness of our method for individual protein studies. Our method would help to characterize the most likely functional phosphorylation sites for further studies in this research area.

MATERIALS AND METHODS

Web server development

In our pipeline, we first predicted all possible phosphorylation sites for a protein with NetPhos (Blom et al., 1999) and NetPhosK (Blom et al.,

Table 6 Cyclin-dependent kinase inhibitor 1B predicted phosphorylation sites

Rank	Sequence	Site	Residue	Validated	Absolute conservation score	Relative conservation score
1	P46527	83	S	yes	0.91213	0.9451900
2	P46527	187	T	yes	0.89140	0.9250400
3	P46527	74	Y	yes	0.80464	0.8947000
4	P46527	161	S	no	0.91181	0.8888900
5	P46527	178	S	yes	0.42948	0.8449600
6	P46527	10	S	yes	0.91213	0.8214100
7	P46527	110	S	no	0.71083	0.8168600
8	P46527	175	S	no	0.38966	0.7975000
9	P46527	27	S	no	0.91213	0.7801300
10	P46527	7	S	yes	0.91213	0.7548800
11	P46527	160	S	no	0.74949	0.7440600
12	P46527	198	T	yes	0.42011	0.7163300
13	P46527	140	S	yes	0.46412	0.7131600
14	P46527	138	S	no	0.10456	0.1775700
15	P46527	128	T	no	0.21473	0.1357200
16	P46527	183	S	no	0.12140	0.1085000
17	P46527	157	T	yes	0.04299	0.0915960
18	P46527	42	T	no	0.31554	0.0580880
19	P46527	12	S	yes	0.37267	0.0068863

2004), which are two existing computational methods for non-kinase-specific and kinase-specific prediction, respectively. The prediction results from other phosphorylation site prediction methods can also be provided as a formatted table (the table template can be downloaded from the web server). We incorporated PhosphoSitePlus (Hornbeck et al., 2012), which is a database containing experimentally validated phosphorylation sites, to mark whether a predicted phosphorylation site is experimentally validated or not.

For conservation score calculation, we used customized Rate4Site with default parameters (Pupko et al., 2002; Mayrose et al., 2004), which can compute the evolutionary rate for each site in a multiple sequence alignment. The alignments of ortholog families were downloaded from the NCBI HomoloGene database (Sayers et al., 2012). For the calculation of the absolute conservation score, we normalized the evolutionary rate r of a phosphorylated site according to the rates of all the residues in the protein, i.e.

$$z_{abs} = \frac{r - \mu(r_{all})}{\sigma(r_{all})}$$

Where $\mu(r_{all})$ and $\sigma(r_{all})$ are the mean and standard deviation of the evolutionary rates of all residues. For the calculation of relative conservation score, we normalized r according to the rates of the flanking residues around the phosphorylated site, 5 to the left and 5 to the right, i.e.

$$z_{rel} = \frac{r - \mu(r_{\pm 5})}{\sigma(r_{\pm 5})}$$

We transformed the z_{abs} and z_{rel} scores to [0, 1] by using the probability function of the standard normal distribution.

Human, rat and mouse database construction

We downloaded the proteome sequences of human, rat and mouse from UniProt (Consortium, 2012). Using our method, we predicted the phosphorylation sites of these proteomes. To guarantee the prediction accuracy of our method, we took the phosphorylation sites predicted by both general and kinase-specific methods and having the conservation scores to construct the human, rat and mouse database. We then incorporated PhosphoSitePlus (Hornbeck et al., 2012) to mark whether the predicted sites have been experimentally validated or not.

General and protein-specific prediction

Since the function information of phosphorylation sites is limited, it is difficult to construct a benchmark dataset to test the overall prediction performance of our method. We ranked the predicted phosphorylation sites in the human, rat and mouse database according to the relative conservation score and selected the top 10% of the experimentally validated phosphorylation sites. Then we selected the protein sequences containing these top 10% sites and did KEGG enrichment of such proteins to find whether protein phosphorylation plays an important role in the enriched KEGG pathways.

We used two well-studied proteins, p53 and Cyclin-dependent kinase inhibitor 1B in which phosphorylation plays an important role, to demonstrate the usage of our method for individual protein studies.

ACKNOWLEDGEMENTS

This work was supported by the National Basic Research Program (973 Program) (Nos. 2011CB910204, 2010CB529206 and 2010CB912702), Research Program of Chinese Academy of Sciences (Nos. KSCX2-EW-R-04, KSCX2-YW-R-190 and 2011KIP204), National Natural Science Foundation of China (Grant Nos. 30900272 and 31070752). Chinese Ministry for Science and Technology Grant (No. 2008BAI64B01) and the National High Technology Research and Development Program (863 Program) (No. 2009AA02Z304).

REFERENCES

- Acosta-Jaquez, H.A., Keller, J.A., Foster, K.G., Ekim, B., Soliman, G.A., Feener, E.P., Ballif, B.A., and Fingar, D.C. (2009). Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. *Mol Cell Biol* 29, 4308–4324.
- Adachi, S., Yasuda, I., Nakashima, M., Yamauchi, T., Yamauchi, J., Natsume, H., Moriwaki, H., and Kozawa, O. (2010). HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells. *Oncol Rep* 23, 1709–1714.
- Aguirre, V., Werner, E.D., Giraud, J., Lee, Y.H., Shoelson, S.E., and White, M.F. (2002). Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. *J Biol Chem* 277, 1531–1537.
- Alevriadou, B.R. (2003). CAMs and Rho small GTPases: gatekeepers for leukocyte transendothelial migration. Focus on "VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration". *Am J Physiol Cell Physiol* 285, C250–252.
- Allingham, M.J., van Buul, J.D., and Burrige, K. (2007). ICAM-1-mediated, Src- and Pyk2-dependent vascular endothelial cadherin tyrosine phosphorylation is required for leukocyte transendothelial migration. *J Immunol* 179, 4053–4064.
- Altomare, D.A., Wang, H.Q., Skele, K.L., De Rienzo, A., Klein-Szanto, A.J., Godwin, A.K., and Testa, J.R. (2004). AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. *Oncogene* 23, 5853–5857.
- Andreozzi, F., Laratta, E., Sciacqua, A., Perticone, F., and Sesti, G. (2004). Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. *Circ Res* 94, 1211–1218.
- Andriopoulou, P., Navarro, P., Zanetti, A., Lampugnani, M.G., and Dejana, E. (1999). Histamine induces tyrosine phosphorylation of endothelial cell-to-cell adherens junctions. *Arterioscl Thromb Vas* 19, 2286–2297.
- Anfinogenova, Y., Wang, R.P., Li, Q.F., Spinelli, A.M., and Tang, D.D. (2007). Important role of Abelson tyrosine kinase (Abl) in regulating vascular smooth muscle contraction. *Faseb J* 21, A1299–A1300.
- Aono, S., and Hirai, Y. (2008). Phosphorylation of claudin-4 is required for tight junction formation in a human keratinocyte cell line.

- Exp Cell Res 314, 3326–3339.
- Arai, S., Matsushita, A., Du, K., Yagi, K., Okazaki, Y., and Kurokawa, R. (2007). Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9. *FEBS Lett* 581, 5649–5657.
- Arber, S., Barbayannis, F.A., Hanser, H., Schneider, C., Stanyon, C.A., Bernard, O., and Caroni, P. (1998). Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. *Nature* 393, 805–809.
- Arevalo, J.C., Pereira, D.B., Yano, H., Teng, K.K., and Chao, M.V. (2006). Identification of a switch in neurotrophin signaling by selective tyrosine phosphorylation. *J Biol Chem* 281, 1001–1007.
- Atherton-Fessler, S., Hannig, G., and Piwnica-Worms, H. (1993). Reversible tyrosine phosphorylation and cell cycle control. *Semin Cell Biol* 4, 433–442.
- Atkins, C.M., Chen, S.J., Klann, E., and Sweatt, J.D. (1997). Increased phosphorylation of myelin basic protein during hippocampal long-term potentiation. *J Neurochem* 68, 1960–1967.
- Aubin, J., Davy, A., and Soriano, P. (2004). In vivo convergence of BMP and MAPK signaling pathways: impact of differential Smad1 phosphorylation on development and homeostasis. *Gene Dev* 18, 1482–1494.
- Aubol, B.E., Ungs, L., Lukasiewicz, R., Ghosh, G., and Adams, J.A. (2004). Chemical clamping allows for efficient phosphorylation of the RNA carrier protein Npl3. *J Biol Chem* 279, 30182–30188.
- Ba, A.N., and Moses, A.M. (2010). Evolution of characterized phosphorylation sites in budding yeast. *Mol Biol Evol* 27, 2027–2037.
- Barberis, L., Pasquali, C., Bertschy-Meier, D., Cuccurullo, A., Costa, C., Ambroggi, C., Vilbois, F., Chiarle, R., Wymann, M., Altruda, F., et al. (2009). Leukocyte transmigration is modulated by chemokine-mediated PI3K gamma-dependent phosphorylation of vimentin. *Eur J Immunol* 39, 1136–1146.
- Barria, A., Muller, D., Derkach, V., Griffith, L.C., and Soderling, T.R. (1997). Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation. *Science* 276, 2042–2045.
- Bianchini, A., Loiarro, M., Bielli, P., Busa, R., Paronetto, M.P., Loreni, F., Geremia, R., and Sette, C. (2008). Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. *Carcinogenesis* 29, 2279–2288.
- Blaydes, J.P., Luciani, M.G., Pospisilova, S., Ball, H.M.L., Vojtesek, B., and Hupp, T.R. (2001). Stoichiometric phosphorylation of human p53 at Ser(315) stimulates p53-dependent transcription. *J Biol Chem* 276, 4699–4708.
- Blom, N., Gammeltoft, S., and Brunak, S. (1999). Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. *J Mol Biol* 294, 1351–1362.
- Blom, N., Sicheritz-Ponten, T., Gupta, R., Gammeltoft, S., and Brunak, S. (2004). Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. *Proteomics* 4, 1633–1649.
- Boehm, M., Yoshimoto, T., Crook, M.F., Nallamshetty, S., True, A., Nabel, G.J., and Nabel, E.G. (2002). A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. *EMBO J* 21, 3390–3401.
- Bornhauser, B.C., and Lindholm, D. (2005). MSAP enhances migration of C6 glioma cells through phosphorylation of the myosin regulatory light chain. *Cell Mol Life Sci* 62, 1260–1266.
- Bouzioukh, F., Wilkinson, G.A., Adelmann, G., Frotscher, M., Stein, V., and Klein, R. (2007). Tyrosine phosphorylation sites in ephrinB2 are required for hippocampal long-term Potentiation but not long-term depression. *J Neurosci* 27, 11279–11288.
- Bradbury, E.M., Inglis, R.J., and Matthews, H.R. (1974). Control of cell-division by very lysine rich histone (F1) phosphorylation. *Nature* 247, 257–261.
- Brunton, V.G., Avizienyte, E., Fincham, V.J., Serrels, B., Metcalf, C.A., Sawyer, T.K., and Frame, M.C. (2005). Identification of Src-specific phosphorylation site on focal adhesion kinase: Dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. *Cancer Res* 65, 1335–1342.
- Busino, L., Chiesa, M., Draetta, G.F., and Donzelli, M. (2004). Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. *Oncogene* 23, 2050–2056.
- Butowt, R., and von Bartheld, C.S. (2009). Fates of neurotrophins after retrograde axonal transport: phosphorylation of p75NTR is a sorting signal for delayed degradation. *J Neurosci* 29, 10715–10729.
- Caenepeel, S., Charydczak, G., Sudarsanam, S., Hunter, T., and Manning, G. (2004). The mouse kinome: Discovery and comparative genomics of all mouse protein kinases. *Proc Natl Acad Sci U S A* 101, 11707–11712.
- Cai, N., Li, M., Qu, J., Liu, G.H., and Izpisua Belmonte, J.C. (2012). Post-translational modulation of pluripotency. *J Mol Cell Biol.* (In Press).
- Calalb, M.B., Polte, T.R., and Hanks, S.K. (1995). Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase-activity - a role for src family kinases. *Mol Cell Biol* 15, 954–963.
- Cappuzzo, F., Magrini, E., Ceresoli, G.L., Bartolini, S., Rossi, E., Ludovini, V., Gregorc, V., Ligorio, C., Cancellieri, A., Damiani, S., et al. (2004). Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. *J Natl Cancer Inst* 96, 1133–1141.
- Capron, B., Wattiez, R., Sindic, C., Godaux, E., and Ris, L. (2007). Tyrosine phosphorylation of rabphilin during long-lasting long-term potentiation. *Neurosci Lett* 414, 257–262.
- Carriere, A., Cargnello, M., Julien, L.A., Gao, H., Bonneil, E., Thibault, P., and Roux, P.P. (2008). Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated Raptor phosphorylation. *Curr Biol* 18, 1269–1277.
- Chang, N.S., Doherty, J., Ensign, A., Schultz, L., Hsu, L.J., and Hong, Q.Y. (2005). WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. *J Biol Chem* 280, 43100–43108.
- Chen, H.C., Appeddu, P.A., Isoda, H., and Guan, J.L. (1996). Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. *J Biol Chem* 271, 26329–26334.
- Chen, S.Y., Xu, Y.Y., Yuan, X., Buble, G.J., and Balk, S.P. (2006). Androgen receptor phosphorylation and stabilization in prostate

- cancer by cyclin-dependent kinase 1. *Proc Natl Acad Sci U S A* 103, 15969–15974.
- Chung, S.H. (2009). Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. *BMB Rep* 42, 467–474.
- Cicenas, J. (2008). The potential role of Akt phosphorylation in human cancers. *Int J Biol Marker* 23, 1–9.
- Clayton, E.L., Sue, N., Smillie, K.J., O'Leary, T., Bache, N., Cheung, G., Cole, A.R., Wyllie, D.J., Sutherland, C., Robinson, P.J., et al. (2010). Dynamin I phosphorylation by GSK3 controls activity-dependent bulk endocytosis of synaptic vesicles. *Nat Neurosci* 13, 845–U885.
- Cohen, P. (2000). The regulation of protein function by multisite phosphorylation—a 25 year update. *Trends Biochem Sci* 25, 596–601.
- Collares-Buzato, C.B., Jepson, M.A., Simmons, N.L., and Hirst, B.H. (1998). Increased tyrosine phosphorylation causes redistribution of adherens junction and tight junction proteins and perturbs paracellular barrier function in MDCK epithelia. *Eur J Cell Biol* 76, 85–92.
- Collawn, J.F. (2006). Unlocking the mysteries of Na⁺-K⁺-ATPase endocytosis - Phosphorylation is the key. *Am J Resp Cell Mol* 35, 1–2.
- Coluccia, A.M.L., Vacca, A., Dunach, M., Mologni, L., Redaelli, S., Bustos, V.H., Benati, D., Pinna, L.A., and Gambacorti-Passerini, C. (2007). Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. *EMBO J* 26, 1456–1466.
- Consortium, U. (2012). Reorganizing the protein space at the Universal Protein Resource (UniProt). *Nucleic Acids Res* 40, D71–D75.
- Copp, J., Manning, G., and Hunter, T. (2009). TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. *Cancer Res* 69, 1821–1827.
- Cousin, M.A., Tan, T.C., and Robinson, P.J. (2001). Protein phosphorylation is required for endocytosis in nerve terminals: potential role for the dephosphins dynamin I and synaptojanin, but not AP180 or amphiphysin. *J Neurochem* 76, 105–116.
- D'Alessandris, C., Lauro, R., Presta, I., and Sesti, G. (2007). C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser(307) and Ser(612) in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. *Diabetologia* 50, 840–849.
- D'Orazi, G., Cecchinelli, B., Bruno, T., Manni, I., Higashimoto, Y., Saito, S., Gostissa, M., Coen, S., Marchetti, A., Del Sal, G., et al. (2002). Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. *Nat Cell Biol* 4, 11–19.
- Dai, N., Rapley, J., Angel, M., Yanik, M.F., Blower, M.D., and Avruch, J. (2011). mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry. *Gene Dev* 25, 1159–1172.
- Dekel, N. (1996). Protein phosphorylation/dephosphorylation in the meiotic cell cycle of mammalian oocytes. *Rev Reprod* 1, 82–88.
- Deming, D., Geiger, P., Chen, H., Kunnimalaiyaan, M., and Holen, K. (2010). ZM336372 induces apoptosis associated with phosphorylation of GSK-3 beta in pancreatic adenocarcinoma cell lines. *J Surg Res* 161, 28–32.
- El Sheikh, S.S., Domin, J., Abel, P., Stamp, G., and Lalani, E.N. (2004). Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. *Neoplasia* 6, 846–853.
- Fan, H.Y., Tong, C., Chen, D.Y., and Sun, Q.Y. (2002). Roles of MAP kinase signaling pathway in oocyte meiosis. *Chinese Sci Bull* 47, 1157–1162.
- Fan, Y.X., Wong, L.L., and Johnson, G.R. (2005). EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without affecting substrate binding affinity. *Biochem J* 392, 417–423.
- Feng, H., Hu, B., Liu, K.W., Li, Y., Lu, X., Cheng, T., Yiin, J.J., Lu, S., Keezer, S., Fenton, T., et al. (2011). Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRalpha-stimulated glioma tumorigenesis in mice and humans. *J Clin Invest* 121, 4670–4684.
- Fernandez-Borja, M., van Buul, J.D., and Hordijk, P.L. (2010). The regulation of leucocyte transendothelial migration by endothelial signalling events. *Cardiovasc Res* 86, 202–210.
- Ficarro, S.B., McClelland, M.L., Stukenberg, P.T., Burke, D.J., Ross, M.M., Shabanowitz, J., Hunt, D.F., and White, F.M. (2002). Phosphoproteome analysis by mass spectrometry and its application to *Saccharomyces cerevisiae*. *Nat Biotechnol* 20, 301–305.
- Finn, G., and Lu, K.P. (2008). Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer. *Curr Cancer Drug Targets* 8, 223–229.
- Foster, J.S., and Wimalasena, J. (1996). Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. *Mol Endocrinol* 10, 488–498.
- Fujii, S., Kuroda, Y., Ito, K., and Kato, H. (2000). Long-term potentiation induction - A synaptic catch mechanism released by extracellular phosphorylation. *Neuroscience* 96, 259–266.
- Fujita, N., Sato, S., Katayama, K., and Tsuruo, T. (2002). Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. *J Biol Chem* 277, 28706–28713.
- Fujita, N., Sato, S., and Tsuruo, T. (2003). Phosphorylation of p27(Kip1) at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. *J Biol Chem* 278, 49254–49260.
- Gnad, F., Ren, S.B., Cox, J., Olsen, J.V., Macek, B., Orosi, M., and Mann, M. (2007). PHOSIDA (phosphorylation site database): management, structural and evolutionary investigation, and prediction of phosphosites. *Genome Biol* 8.
- Gomez, S., Llosas, M.D., Verdu, J., Roura, S., Lloreta, J., Fabre, M., and de Herreros, A.G. (1999). Independent regulation of adherens and tight junctions by tyrosine phosphorylation in Caco-2 cells. *Bba-Mol Cell Res* 1452, 121–132.
- Gual, P., Le Marchand-Brustel, Y., and Tanti, J.F. (2005). Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. *Biochimie* 87, 99–109.
- Haldar, S., Chintapalli, J., and Croce, C.M. (1996). Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. *Cancer Res* 56, 1253–1255.
- Hao, B., Zheng, N., Schulman, B.A., Wu, G., Miller, J.J., Pagano, M., and Pavletich, N.P. (2005). Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. *Mol Cell* 20, 9–19.

- Head, J.A., Jiang, D.Y., Li, M., Zorn, L.J., Schaefer, E.M., Parsons, J.T., and Weed, S.A. (2003). Cortactin tyrosine phosphorylation requires Rac1 activity and association with the cortical actin cytoskeleton. *Mol Biol Cell* 14, 3216–3229.
- Hirano, K., Hirano, M., and Kanaide, H. (2004). Regulation of myosin phosphorylation and myofilament Ca²⁺ sensitivity in vascular smooth muscle. *J Smooth Muscle Res* 40, 219–236.
- Hofmann, T.G., Moller, A., Sirma, H., Zentgraf, H., Taya, Y., Droge, W., Will, H., and Schmitz, M.L. (2002). Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. *Nat Cell Biol* 4, 1–10.
- Hornbeck, P.V., Kornhauser, J.M., Tkachev, S., Zhang, B., Skrzypek, E., Murray, B., Latham, V., and Sullivan, M. (2012). PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. *Nucleic Acids Res* 40, D261–D270.
- Iakoucheva, L.M., Radivojac, P., Brown, C.J., O'Connor, T.R., Sikes, J.G., Obradovic, Z., and Dunker, A.K. (2004). The importance of intrinsic disorder for protein phosphorylation. *Nucleic Acids Res* 32, 1037–1049.
- Itoh, N., Semba, S., Ito, M., Takeda, H., Kawata, S., and Yamakawa, M. (2002). Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. *Cancer* 94, 3127–3134.
- Jaggi, M., Rao, P.S., Smith, D.J., Wheelock, M.J., Johnson, K.R., Hemstreet, G.P., and Balaji, K.C. (2005). E-cadherin phosphorylation by protein kinase D1 protein kinase C mu is associated with altered cellular aggregation and motility in prostate cancer. *Cancer Res* 65, 483–492.
- Jalkanen, S.E., Vakkila, J., Kreutzman, A., Nieminen, J.K., Porkka, K., and Mustjoki, S. (2011). Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy. *Exp Hematol* 39, 102–113 e101.
- Jiang, C., Hu, H.B., Malewicz, B., Wang, Z.S., and Lu, J.X. (2004). Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells. *Mol Cancer Ther* 3, 877–884.
- Jilani, I., Kantarjian, H., Gorre, M., Cortes, J., Ottmann, O., Bhalla, K., Giles, F.J., and Albitar, M. (2008). Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. *Leukemia Res* 32, 643–649.
- Ju, J.W., Bandyopadhyay, A., Im, W.B., Chung, J., Kwon, H.B., and Choi, H.S. (2002). Involvement of phosphatidylinositol 3 kinase in the progesterone-induced oocyte maturation in *Rana dybowskii*. *Gen Comp Endocr* 126, 213–220.
- Junttila, M.R., Li, S.P., and Westermarck, J. (2008). Phosphatase-mediated crosstalk between MAPK signalling pathways in the regulation of cell survival. *Faseb J* 22, 954–965.
- Kanamori, Y., Kigawa, J., Itamochi, H., Shimada, M., Takahashi, M., Kamazawa, S., Sato, S., Akeshima, R., and Terakawa, N. (2001). Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. *Clin Cancer Res* 7, 892–895.
- Kapoor, M., Hamm, R., Yan, W., Taya, Y., and Lozano, G. (2000). Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. *Oncogene* 19, 358–364.
- Karin, M., and Ben-Neriah, Y. (2000). Phosphorylation meets ubiquitination: The control of NF-kappa B activity. *Annu Rev Immunol* 18, 621–663.
- Khadjavi, A., Barbero, G., Destefanis, P., Mandili, G., Giribaldi, G., Mannu, F., Pantaleo, A., Ceruti, C., Bosio, A., Rolle, L., et al. (2011). Evidence of Abnormal Tyrosine Phosphorylated Proteins in the Urine of Patients With Bladder Cancer: The Road Toward a New Diagnostic Tool? *J Urology* 185, 1922–1929.
- Kim, S.J., Rabbani, Z.N., Vollmer, R.T., Schreiber, E.G., Dewhirst, M.W., Vujaskovic, Z., and Kelley, M.J. (2005). Expression of phosphorylated epidermal growth factor receptor (p-EGFR) in early stage non-small cell lung cancer: its relationship with over-expression of EGFR and cyclooxygenase-2 (COX-2), and survival. *J Clin Oncol* 23, 864s–864s.
- Kim, Y., Paroush, Z., Nairz, K., Hafen, E., Jimenez, G., and Shvartsman, S.Y. (2011). Substrate-dependent control of MAPK phosphorylation in vivo. *Mol Syst Biol* 7.
- Kleinman, D., Karas, M., Danilenko, M., Arbeli, A., Roberts, C.T., LeRoith, D., Levy, J., and Sharoni, Y. (1996). Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. *Endocrinology* 137, 1089–1095.
- Koepp, D.M., Schaefer, L.K., Ye, X., Keyomarsi, K., Chu, C., Harper, J.W., and Elledge, S.J. (2001). Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. *Science* 294, 173–177.
- Konishi, Y., Lehtinen, M., Donovan, N., and Bonni, A. (2002). Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. *Mol Cell* 9, 1005–1016.
- Kordowska, J., Huang, R.J., and Wang, C.L.A. (2006). Phosphorylation of caldesmon during smooth muscle contraction and cell migration or proliferation. *J Biomed Sci* 13, 159–172.
- Kornberg, L., Earp, H.S., Parsons, J.T., Schaller, M., and Juliano, R.L. (1992). Cell-adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. *J Biol Chem* 267, 23439–23442.
- Kreisberg, J.I., Malik, S.N., Prihoda, T.J., Bedolla, R.G., Troyer, D.A., Kreisberg, S., and Ghosh, P.M. (2004). Phosphorylation of Akt (Ser(473)) is an excellent predictor of poor clinical outcome in prostate cancer. *Cancer Res* 64, 5232–5236.
- Kruck, S., Bedke, J., Hennenlotter, J., Ohneseit, P.A., Kuehs, U., Senger, E., Sievert, K.D., and Stenzl, A. (2010). Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression. *Oncol Rep* 23, 159–163.
- Landry, C.R., Levy, E.D., and Michnick, S.W. (2009). Weak functional constraints on phosphoproteomes. *Trends Genet* 25, 193–197.
- Lee, E.W., Lee, M.S., Camus, S., Ghim, J., Yang, M.R., Oh, W., Ha, N.C., Lane, D.P., and Song, J. (2009). Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. *EMBO J* 28, 2100–2113.
- Lee, M.G., Norbury, C.J., Spurr, N.K., and Nurse, P. (1988). Regulated expression and phosphorylation of a possible mammalian cell-cycle control protein. *Nature* 333, 676–679.
- Lee, S.H., Kim, H.S., Park, W.S., Kim, S.Y., Lee, K.Y., Kim, S.H., Lee,

- J.Y., and Yoo, N.J. (2002). Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. *APMIS* 110, 587–592.
- Lew, D.J., and Kornbluth, S. (1996). Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. *Curr Opin Cell Biol* 8, 795–804.
- Li, Z.L., Li, J.F., Bu, X.N., Liu, X., Tankersley, C.G., Wang, C., and Huang, K.W. (2011). Age-induced augmentation of p38 MAPK phosphorylation in mouse lung. *Exp Gerontol* 46, 694–702.
- Liang, C.G., Su, Y.Q., Fan, H.Y., Schatten, H., and Sun, Q.Y. (2007). Mechanisms regulating oocyte meiotic resumption: roles of mitogen-activated protein kinase. *Mol Endocrinol* 21, 2037–2055.
- Lin, H.Y., Shih, A., Davis, F.B., Tang, H.Y., Martino, L.J., Bennett, J.A., and Davis, P.J. (2002). Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. *J Urology* 168, 748–755.
- Lonart, G., Schoch, S., Kaeser, P.S., Larkin, C.J., Sudhof, T.C., and Linden, D.J. (2003). Phosphorylation of RIM1 alpha by PKA triggers presynaptic long-term potentiation at cerebellar parallel fiber synapses. *Cell* 115, 49–60.
- Ma, D.J., Wang, J.R., Zhao, Y.C., Lee, W.N.P., Xiao, J., Go, V.L.W., Wang, Q., Recker, R.R., and Xiao, G.G. (2012). Inhibition of glycogen phosphorylation induces changes in cellular proteome and signaling pathways in MIA pancreatic cancer cells. *Pancreas* 41, 397–408.
- Mahajan, N.P., Liu, Y., Majumder, S., Warren, M.R., Parker, C.E., Mohler, J.L., Earp, H.S., and Whang, Y.E. (2007). Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. *Proc Natl Acad Sci U S A* 104, 8438–8443.
- Manabe, T., Aiba, A., Yamada, A., Ichise, T., Sakagami, H., Kondo, H., and Katsuki, M. (2000). Regulation of long-term potentiation by H-Ras through NMDA receptor phosphorylation. *J Neurosci* 20, 2504–2511.
- Manning, G., Plowman, G.D., Hunter, T., and Sudarsanam, S. (2002a). Evolution of protein kinase signaling from yeast to man. *Trends Biochem Sci* 27, 514–520.
- Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002b). The protein kinase complement of the human genome. *Science* 298, 1912–1934.
- Mathew, R., Hartmuth, K., Mohlmann, S., Urlaub, H., Ficner, R., and Luhrmann, R. (2008). Phosphorylation of human PRP28 by SRPK2 is required for integration of the U4/U6-U5 tri-snRNP into the spliceosome. *Nat Struct Mol Biol* 15, 435–443.
- Matsumoto, H., Sakamoto, A., Fujiwara, M., Yano, Y., Shishido-Hara, Y., Fujioka, Y., and Kamma, H. (2008). Cyclic AMP-mediated growth suppression and MAPK phosphorylation in thyroid papillary carcinoma cells. *Mol Med Rep* 1, 245–249.
- Matsuoka, S., Huang, M.X., and Elledge, S.J. (1998). Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. *Science* 282, 1893–1897.
- Mayrose, I., Graur, D., Ben-Tal, N., and Pupko, T. (2004). Comparison of site-specific rate-inference methods for protein sequences: empirical Bayesian methods are superior. *Mol Biol Evol* 21, 1781–1791.
- McDonough, W.S., Tran, N.L., and Berens, M.E. (2005). Regulation of glioma cell migration by serine-phosphorylated P311. *Neoplasia* 7, 862–872.
- McManus, E.J., Sakamoto, K., Armit, L.J., Ronaldson, L., Shpiro, N., Marquez, R., and Alessi, D.R. (2005). Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. *EMBO J* 24, 1571–1583.
- Mermoud, J.E., Cohen, P.T.W., and Lamond, A.I. (1994). Regulation of mammalian spliceosome assembly by a protein-phosphorylation mechanism. *EMBO J* 13, 5679–5688.
- Mimura, Y., Ihn, H., Jinnin, M., Asano, Y., Yamane, K., and Tamaki, K. (2005). Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. *J Invest Dermatol* 124, 886–892.
- Miyata, Y., Sagara, Y., Kanda, S., Hayashi, T., and Kanetake, H. (2009). Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and-7 and E-cadherin. *Hum Pathol* 40, 496–504.
- Morrison, D.K., Murakami, M.S., and Clegghon, V. (2000). Protein kinases and phosphatases in the Drosophila genome. *J Cell Biol* 150, F57–F62.
- Motti, M.L., De Marco, C., Califano, D., Fusco, A., and Viglietto, G. (2004). Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer. *Cell Cycle* 3, 1074–1080.
- Muller, W.A. (2009). Mechanisms of transendothelial migration of leukocytes. *Circ Res* 105, 223–230.
- Mulner, O., Megret, F., Alouf, J.E., and Ozon, R. (1985). Pertussis toxin facilitates the progesterone-induced maturation of *Xenopus* oocyte. Possible role of protein phosphorylation. *FEBS Lett* 181, 397–402.
- Muslin, A.J., Macnicol, A.M., and Williams, L.T. (1993). Raf-1 protein-kinase is important for progesterone-induced *xenopus*-oocyte maturation and acts downstream of Mos. *Mol Cell Biol* 13, 4197–4202.
- Mutoh, T., Sobue, G., Hamano, T., Kuriyama, M., Hirayama, M., Yamamoto, M., and Mitsuma, T. (2000). Decreased phosphorylation levels of TrkB neurotrophin receptor in the spinal cords from patients with amyotrophic lateral sclerosis. *Neurochem Res* 25, 239–245.
- Myers, M.G., Mendez, R., Shi, P., Pierce, J.H., Rhoads, R., and White, M.F. (1998). The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling. *J Biol Chem* 273, 26908–26914.
- Mylonis, I., Chachami, G., Samiotaki, M., Panayotou, G., Paraskeva, E., Kalousi, A., Georgatsou, E., Bonanou, S., and Simos, G. (2006). Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1 alpha. *J Biol Chem* 281, 33095–33106.
- Nakada, M., Anderson, E.M., Demuth, T., Nakada, S., Reavie, L.B., Drake, K.L., Hoelzinger, D.B., and Berens, M.E. (2010). The phosphorylation of ephrin-B2 ligand promotes glioma cell migration and invasion. *Int J Cancer* 126, 1155–1165.
- Nakada, M., Niska, J.A., Miyamori, H., McDonough, W.S., Wu, J., Sato, H., and Berens, M.E. (2004). The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. *Cancer Res* 64, 3179–3185.
- Nakashima, M., Adachi, S., Yasuda, I., Yamauchi, T., Kawaguchi, J.,

- Itani, M., Yoshioka, T., Matsushima-Nishiwaki, R., Hirose, Y., Kozawa, O., et al. (2011). Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells. *Cancer Lett* 313, 218–225.
- Nebreda, A.R., Gannon, J.V., and Hunt, T. (1995). Newly synthesized protein(s) must associate with P34(Cdc2) to activate Map kinase and Mpf during progesterone-induced maturation of *Xenopus* oocytes. *EMBO J* 14, 5597–5607.
- Ng, S.S.W., Tsao, M.S., Nicklee, T., and Hedley, D.W. (2001). Wortmannin inhibits PKB/Akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. *Clin Cancer Res* 7, 3269–3275.
- Nigam, S.K., Denisenko, N., Rodriguezboulant, E., and Citi, S. (1991). The role of phosphorylation in development of tight junctions in cultured renal epithelial (Mdkc) cells. *Biochem Biophys Res Commun* 181, 548–553.
- Nucifora, P.G.P., and Fox, A.P. (1999). Tyrosine phosphorylation regulates rapid endocytosis in adrenal chromaffin cells. *J Neurosci* 19, 9739–9746.
- Oda, A., Miyakawa, Y., Druker, B.J., Ishida, A., Ozaki, K., Ohashi, H., Wakui, M., Handa, M., Watanabe, K., Okamoto, S., et al. (1996). Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. *Blood* 88, 4304–4313.
- Ollila, S., and Makela, T.P. (2011). The tumor suppressor kinase LKB1: lessons from mouse models. *J Mol Cell Biol* 3, 330–340.
- Ou, T.T., Wu, C.H., Hsu, J.D., Chyau, C.C., Lee, H.J., and Wang, C.J. (2011). *Paeonia lactiflora* Pall inhibits bladder cancer growth involving phosphorylation of Chk2 in vitro and in vivo. *J Ethnopharmacol* 135, 162–172.
- Oude Weernink, P.A., Verheul, E., Kerkhof, E., van Veelen, C.W., and Rijkssen, G. (1996). Inhibitors of protein tyrosine phosphorylation reduce the proliferation of two human glioma cell lines. *Neurosurgery* 38, 108–113.
- Park, J., Sung, J.Y., Park, J., Song, W.J., Chang, S., and Chung, K.C. (2012). Dyrk1A negatively regulates the actin cytoskeleton through threonine phosphorylation of N-WASP. *J Cell Sci* 125, 67–80.
- Pinna, L.A., and Ruzzene, M. (1996). How do protein kinases recognize their substrates? *Biochim Biophys Acta* 1314, 191–225.
- Pupko, T., Bell, R.E., Mayrose, I., Glaser, F., and Ben-Tal, N. (2002). Rate4Site: an algorithmic tool for the identification of functional regions in proteins by surface mapping of evolutionary determinants within their homologues. *Bioinformatics* 18 Suppl 1, S71–77.
- Rao, R. (2009). Occludin phosphorylation in regulation of epithelial tight junctions. *Ann N Y Acad Sci* 1165, 62–68.
- Rosner, M., Siegel, N., Valli, A., Fuchs, C., and Hengstschlager, M. (2010). mTOR phosphorylated at S2448 binds to raptor and rictor. *Amino Acids* 38, 223–228.
- Sabile, A., Meyer, A.M., Wirbelauer, C., Hess, D., Kogel, U., Scheffner, M., and Krek, W. (2006). Regulation of p27 degradation and S-phase progression by Ro52 RING finger protein. *Mol Cell Biol* 26, 5994–6004.
- Sakaguchi, K., Sakamoto, H., Lewis, M.S., Anderson, C.W., Erickson, J.W., Appella, E., and Xie, D. (1997). Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. *Biochemistry-US* 36, 10117–10124.
- Sallee, J.L., and Burridge, K. (2009). Density-enhanced phosphatase 1 regulates phosphorylation of tight junction proteins and enhances barrier function of epithelial cells. *J Biol Chem* 284, 14997–15006.
- Sayers, E.W., Barrett, T., Benson, D.A., Bolton, E., Bryant, S.H., Canese, K., Chetvermin, V., Church, D.M., DiCuccio, M., Federhen, S., et al. (2012). Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res* 40, D13–D25.
- Schaefer, A.W., Kamei, Y., Kamiguchi, H., Wong, E.V., Rapoport, I., Kirchhausen, T., Beach, C.M., Landreth, G., Lemmon, S.K., and Lemmon, V. (2002). L1 endocytosis is controlled by a phosphorylation-dephosphorylation cycle stimulated by outside-in signaling by L1. *J Cell Biol* 157, 1223–1232.
- Schafe, G.E., Swank, M.W., Rodrigues, S.M., Debiec, J., and Doyere, V. (2008). Phosphorylation of ERK/MAP kinase is required for long-term potentiation in anatomically restricted regions of the lateral amygdala in vivo. *Learn Memory* 15, 55–62.
- Schmidt, N., Akaaboune, M., Gajendran, N., Martinez-Pena y Valenzuela, I., Wakefield, S., Thurnheer, R., and Brenner, H.R. (2011). Neuregulin/ErbB regulate neuromuscular junction development by phosphorylation of alpha-dystrobrevin. *J Cell Biol* 195, 1171–1184.
- Serrano, P., Yao, Y., and Sacktor, T.C. (2005). Persistent phosphorylation by protein kinase Mzeta maintains late-phase long-term potentiation. *J Neurosci* 25, 1979–1984.
- Serres, M., Filhol, O., Lickert, H., Grangeasse, C., Chambaz, E.M., Stappert, J., Vincent, C., and Schmitt, D. (2000). The disruption of adherens junctions is associated with a decrease of E-cadherin phosphorylation by protein kinase CK2. *Exp Cell Res* 257, 255–264.
- Shasby, D.M., Ries, D.R., Shasby, S.S., and Winter, M.C. (2002). Histamine stimulates phosphorylation of adherens junction proteins and alters their link to vimentin. *Am J Physiol-Lung C* 282, L1330–L1338.
- Shen, L., Black, E.D., Witkowski, E.D., Lencer, W.I., Guerriero, V., Schneeberger, E.E., and Turner, J.R. (2006). Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure. *J Cell Sci* 119, 2095–2106.
- Shimada, K., Nakamura, M., Ishida, E., and Konishi, N. (2006). Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer. *Histol Histopathol* 21, 415–422.
- Shouse, G.P., Cai, X., and Liu, X. (2008). Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. *Mol Cell Biol* 28, 448–456.
- Skowyra, D., Craig, K.L., Tyers, M., Elledge, S.J., and Harper, J.W. (1997). F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. *Cell* 91, 209–219.
- Slack, B.E. (1998). Tyrosine phosphorylation of paxillin and focal adhesion kinase by activation of muscarinic m3 receptors is dependent on integrin engagement by the extracellular matrix. *Proc Natl Acad Sci U S A* 95, 7281–7286.
- Slepnev, V.I., Ochoa, G.C., Butler, M.H., Grabs, D., and De Camilli, P. (1998). Role of phosphorylation in regulation of the assembly of

- endocytic coat complexes. *Science* 281, 821–824.
- Soubeyrand, S., Schild-Poulter, C., and Hache, R.J.G. (2004). Structured DNA promotes phosphorylation of p53 by DNA-dependent protein kinase at serine 9 and threonine 18. *Eur J Biochem* 271, 3776–3784.
- Sumi, T., Matsumoto, K., Takai, Y., and Nakamura, T. (1999). Cofilin phosphorylation and actin cytoskeletal dynamics regulated by Rho- and Cdc42-activated LIM-kinase 2. *J Cell Biol* 147, 1519–1532.
- Swain, J.E., and Smith, G.D. (2007). Reversible phosphorylation and regulation of mammalian oocyte meiotic chromatin remodeling and segregation. *Soc Reprod Fertil Suppl* 63, 343–358.
- Sweeney, C., and Carraway, K.L. (2000). Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. *Oncogene* 19, 5568–5573.
- Szanto, A., Bognar, Z., Szigeti, A., Szabo, A., Farkas, L., and Gallyas, F. (2009). Critical role of bad phosphorylation by Akt in cytosolic resistance of human bladder cancer cells. *Anticancer Res* 29, 159–164.
- Tang, D., Mehta, D., and Gunst, S.J. (1999). Mechanosensitive tyrosine phosphorylation of paxillin and focal adhesion kinase in tracheal smooth muscle. *Am J Physiol-Cell Ph* 276, C250–C258.
- Tang, J.M., He, Q.Y., Guo, R.X., and Chang, X.J. (2006). Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. *Lung Cancer* 51, 181–191.
- Tanti, J.F., and Jager, J. (2009). Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. *Curr Opin Pharmacol* 9, 753–762.
- Terakawa, N., Kanamori, Y., and Yoshida, S. (2003). Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. *Endocr-Relat Cancer* 10, 203–208.
- Tinsley, J.H., Wu, M.H., Ma, W.Y., Taulman, A.C., and Yuan, S.Y. (1999). Activated neutrophils induce hyperpermeability and phosphorylation of adherens junction proteins in coronary venular endothelial cells. *J Biol Chem* 274, 24930–24934.
- Topisirovic, I., Ruiz-Gutierrez, M., and Borden, K.L.B. (2004). Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. *Cancer Res* 64, 8639–8642.
- Tsurutani, J., Fukuoka, J., Tsurutani, H., Shih, J.H., Hewitt, S.M., Travis, W.D., Jen, J., and Dennis, P.A. (2006). Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. *J Clin Oncol* 24, 306–314.
- Ubersax, J.A., and Ferrell, J.E., Jr. (2007). Mechanisms of specificity in protein phosphorylation. *Nat Rev Mol Cell Biol* 8, 530–541.
- Ueki, K., Kondo, T., and Kahn, C.R. (2004). Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. *Mol Cell Biol* 24, 5434–5446.
- Ueno, M., Carnevali, J.B.C., Tambascia, R.C., Bezerra, R.M.N., Amaral, M.E., Carneiro, E.M., Folli, F., Franchini, K.G., and Saad, M.J.A. (2005). Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. *Diabetologia* 48, 506–518.
- van der Horst, E.H., Weber, I., and Ullrich, A. (2005). Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: Novel heregulin/HER3-stimulated signaling pathway in glioma. *International Journal of Cancer* 113, 689–698.
- Vardouli, L., Moustakas, A., and Stoumaras, C. (2005). LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta. *J Biol Chem* 280, 11448–11457.
- Viatour, P., Merville, M.P., Bours, V., and Chariot, A. (2005). Phosphorylation of NF-kappa B and I kappa B proteins: implications in cancer and inflammation. *Trends Biochem Sci* 30, 43–52.
- Viegi, A., Cotrufo, T., Berardi, N., Mascia, L., and Maffei, L. (2002). Effects of dark rearing on phosphorylation of neurotrophin Trk receptors. *Eur J Neurosci* 16, 1925–1930.
- Viglietto, G., Motti, M.L., Bruni, P., Melillo, R.M., D'Alessio, A., Califano, D., Vinci, F., Chiappetta, G., Tschlis, P., Bellacosa, A., et al. (2002). Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. *Nat Med* 8, 1136–1144.
- Vivanco, I., and Sawyers, C.L. (2002). The phosphatidylinositol 3-kinase-AKT pathway in human cancer. *Nat Rev Cancer* 2, 489–501.
- Vo, K., Amarasinghe, B., Washington, K., Gonzalez, A., Berlin, J., and Dang, T.P. (2011). Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation. *Mol Cancer* 10, 138.
- Volberg, T., Zick, Y., Dror, R., Sabanay, I., Gilon, C., Levitzki, A., and Geiger, B. (1992). The effect of tyrosine-specific protein-phosphorylation on the assembly of adherens-type junctions. *EMBO J* 11, 1733–1742.
- Walker, J.S., Wingard, C.J., and Murphy, R.A. (1994). Energetics of crossbridge phosphorylation and contraction in vascular smooth-muscle. *Hypertension* 23, 1106–1112.
- Wang, C.H., Mao, X.M., Wang, L.X., Liu, M.L., Wetzel, M.D., Guan, K.L., Dong, L.Q., and Liu, F. (2007). Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. *J Biol Chem* 282, 7991–7996.
- Wang, H., Owens, C., Chandra, N., Conaway, M.R., Brautigan, D.L., and Theodorescu, D. (2010). Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. *Cancer Res* 70, 8760–8769.
- Wang, J.J.L., Tasinato, A., Ethell, D.W., Testa, M.P., and Bredesen, D.E. (2000). Phosphorylation of the common neurotrophin receptor p75 by p38 beta 2 kinase affects NF-kappa B and AP-1 activities. *J Mol Neurosci* 15, 19–29.
- Wang, Q., Wang, C.M., Ai, J.S., Xiong, B., Yin, S., Hou, Y., Chen, D.Y., Schatten, H., and Sun, Q.Y. (2006a). Histone phosphorylation and pericentromeric histone modifications in oocyte meiosis. *Cell Cycle* 5, 1974–1982.
- Wang, X., Bruderer, S., Rafi, Z., Xue, J., Milburn, P.J., Kramer, A., and Robinson, P.J. (1999). Phosphorylation of splicing factor SF1 on Ser20 by cGMP-dependent protein kinase regulates spliceosome assembly. *EMBO J* 18, 4549–4559.
- Wang, Y.G., Du, D., Fang, L.H., Yang, G., Zhang, C.Y., Zeng, R.,

- Ullrich, A., Lottspeich, F., and Chen, Z.J. (2006b). Tyrosine phosphorylated Par3 regulates epithelial tight junction assembly promoted by EGFR signaling. *EMBO J* 25, 5058–5070.
- Whistler, J.L., Tsao, P., and von Zastrow, M. (2001). A phosphorylation-regulated brake mechanism controls the initial endocytosis of opioid receptors but is not required for post-endocytic sorting to lysosomes. *J Biol Chem* 276, 34331–34338.
- Willems, A.R., Goh, T., Taylor, L., Chernushevich, I., Shevchenko, A., and Tyers, M. (1999). SCF ubiquitin protein ligases and phosphorylation-dependent proteolysis. *Philos T Roy Soc B* 354, 1533–1550.
- Willems, A.R., Lanker, S., Patton, E.E., Craig, K.L., Nason, T.F., Mathias, N., Kobayashi, R., Wittenberg, C., and Tyers, M. (1996). Cdc53 targets phosphorylated G1 cyclins for degradation by the ubiquitin proteolytic pathway. *Cell* 86, 453–463.
- Wong, Y.H., Lee, T.Y., Liang, H.K., Huang, C.M., Wang, T.Y., Yang, Y.H., Chu, C.H., Huang, H.D., Ko, M.T., and Hwang, J.K. (2007). KinasePhos 2.0: a web server for identifying protein kinase-specific phosphorylation sites based on sequences and coupling patterns. *Nucleic Acids Res* 35, W588–594.
- Xue, Y., Li, A., Wang, L.R., Feng, H.Q., and Yao, X.B. (2006). PPSP: prediction of PK-specific phosphorylation site with Bayesian decision theory. *BMC Bioinformatics* 7, 163.
- Xue, Y., Liu, Z., Cao, J., Ma, Q., Gao, X., Wang, Q., Jin, C., Zhou, Y., Wen, L., and Ren, J. (2011). GPS 2.1: enhanced prediction of kinase-specific phosphorylation sites with an algorithm of motif length selection. *Protein Eng Des Sel* 24, 255–60.
- Yamamoto, N., Mammadova, G., Song, R.X.D., Fukami, Y., and Sato, K. (2006). Tyrosine phosphorylation of p145(met) mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. *J Cell Sci* 119, 4623–4633.
- Yu, X.C., and Chen, J.J. (2004). DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. *Mol Cell Biol* 24, 9478–9486.
- Zannini, L., Buscemi, G., Kim, J.E., Fontanella, E., and Delia, D. (2012). DBC1 phosphorylation by ATM/ATR inhibits SIRT1 deacetylase in response to DNA damage. *J Mol Cell Biol*. (In Press).
- Zhang, T., Mi, Z.P., and Schor, N.F. (2009). Role of tyrosine phosphorylation in the antioxidant effects of the p75 neurotrophin receptor. *Oxid Med Cell Longev* 2, 238–246.
- Zhang, Y.J., Lu, C.R., Cao, Y., Luo, Y., Bao, R.F., Yan, S., Xue, M., Zhu, F., Wang, Z., and Duan, L.N. (2012). Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway. *Acta Pharmacol Sin* 33, 551–557.
- Zhang, Y.W., Moreland, S., and Moreland, R.S. (1994). Regulation of vascular smooth-muscle contraction-myosin light-chain phosphorylation-dependent and independent pathways. *Can J Physiol Pharm* 72, 1386–1391.
- Zheng, L., Foley, K., Huang, L.Q., Leubner, A., Mo, G.L., Olino, K., Edil, B.H., Mizuma, M., Sharma, R., Le, D.T., et al. (2011). Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. *Plos One* 6, e19390.
- Zhou, Y.F., Jiang, H., Tang, J.G., and Tang, B.S. (2008). [The advances in research on phosphorylation of polyglutamine disease]. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 25, 414–417.
- Zhu, J.W., Yu, D., Zeng, X.C., Zhou, K., and Zhan, X. (2007). Receptor-mediated endocytosis involves tyrosine phosphorylation of cortactin. *J Biol Chem* 282, 16086–16094.
- Zick, Y. (2001). Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. *Trends Cell Biol* 11, 437–441.
- Zolnierowicz, S., and Bollen, M. (2000). Protein phosphorylation and protein phosphatases. *De Panne, Belgium*, September 19–24, 1999. *EMBO J* 19, 483–488.